Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.

Sylvia DrazilovaJanicko MartinLubomir SkladanyPavol KristianMarian OltmanMaria SzantovaDusan KrkoskaEva MazuchovaLubica PieseckaVeronika VahalovaMarek RacIvan SchreterLadislav ViragTomas KollerAdriana LiptakovaMiriam OndrasovaJarcuska Peter

Published in: Canadian journal of gastroenterology & hepatology (2018)

We confirmed that the prevalence of either T2DM or IFG increases in chronic hepatitis C patients with the degree of fibrosis. The predictive factors for T2DM were, besides F4, fibrosis also higher age and BMI. Significant decrease of fasting glycemia after the DAA treatment was observed in the whole cohort and in subgroups of patients with T2DM, IFG, cirrhotic, and treatment experienced patients.

Keyphrases

end stage renal disease
newly diagnosed
liver fibrosis
ejection fraction
body mass index
type diabetes
prognostic factors
peritoneal dialysis
blood pressure
combination therapy
skeletal muscle
physical activity
weight gain
replacement therapy
patient reported